Genentech Is Second Biologic Titan To Resolve Trade Secret Suit; Former Employees Still On Hook
Executive Summary
Genentech reaches memorandum of understanding with JHL Biotech involving four biosimilars while continuing its suit against former employees; Amgen settlement with Coherus ended litigation entirely.
You may also be interested in...
Fate Of JHL Biotech's Biosimilars Uncertain As Judge Bars Use Of Genentech Trade Secrets
Court denies JHL motion to dismiss trade secret theft suit, bars development or sale of biosimilars that rely on information from Genentech documents; trial scheduled to begin in November 2020.
Teva US settles with Apotex on collusion
Teva and Apotex have settled litigation in the US over allegations Teva’s former senior director of regulatory affairs for US generics, Barinder Sandhu, misappropriated trade secrets and shared them with Apotex’ erstwhile chief executive officer Jeremy Desai while the pair were in “a romantic relationship”.
Amgen Alleges 'Massive Conspiracy' By Employees Who Joined Coherus And KBI
Details emerge on the breadth of Amgen's complaint against Coherus and former Amgen employees; trade secrets on Neulasta pricing and contract strategies allegedly stolen via USB drives.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: